Balance Sheet Account Detail (Tables)

12 Months Ended

Dec. 31, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Cash and Cash Equivalents and Marketable Securities

The following is a summary of our presented composition of “cash and cash equivalents” and “marketable securities”:

	Historical or Amortized Cost		Foreign Currency Translation			Unrealized Gains		Unrealized Losses			Fair Value		Cash and Cash equivalents		Marketable Securities
December 31, 2019
Equity securities* (see Note 8)	$	6,310	$	(2,477	)	$	27,214	$	—		$	31,047	$	—	$	31,047
Money market funds	54,199		—			—		—			54,199		54,199		—
Government-related debt securities**	62,617		—			19		(10		)	62,626		—		62,626
Corporate debt securities**	58,235		—			38		(25		)	58,248		5,000		53,248
Bank deposits	5,219		—			—		—			5,219		5,219		—
Mutual funds	4,375		—			783		—			5,158		—		5,158
Bank CDs	7,354		—			22		—			7,376		—		7,376
Total cash and cash equivalents and marketable securities	$	198,309	$	(2,477	)	$	28,076	$	(35	)	$	223,873	$	64,418	$	159,455
December 31, 2018
Equity securities*	$	8,710	$	(2,168	)	$	39,880	$	—		$	46,422	$	—	$	46,422
Money market funds	142,745		—			—		—			142,745		142,745		—
Bank deposits	14,735		—			—		—			14,735		14,735		—
Bank CDs	86		—			—		—			86		—		86
Total cash and cash equivalents and marketable securities	$	166,276	$	(2,168	)	$	39,880	$	—		$	203,988	$	157,480	$	46,508

* Beginning January 1, 2018, under the new requirements of ASU 2016-01, Recognition and Measurement of Financial Assets and Liabilities, the unrealized gains (losses) on our CASI equity securities are recognized as an increase (decrease) to “other (expense) income, net” on the Consolidated Statements of Operations (rather than through “other comprehensive loss” on the Consolidated Statements of Comprehensive Loss). Our adoption of ASU 2016-01 on January 1, 2018, resulted in a $17.2 million cumulative-effect adjustment, net of income tax, reported as a decrease to “accumulated other comprehensive loss” and a decrease to “accumulated deficit” on the accompanying Consolidated Balance Sheets. Our unrealized (losses) gains on these equity securities for the year ended December 31, 2019 and 2018 was $(12.7) million and 10.5 million, respectively, as reported in “other (expense) income, net” on the accompanying Consolidated Statements of Operations.

** Beginning in the second quarter of 2019, we purchased certain government-related and corporate debt securities. We have classified these as “available-for-sale” since we may redeem or sell these investments before their stated maturity to fund our operations. Under the requirements of ASC 320, Investments - Debt and Equity Securities: (i) we recorded these securities at initial “book value” and then amortize, through maturity, the determined “discount” or “premium” within “interest income” on the accompanying Consolidated Statements of Operations, and (ii) we recognize the “unrealized gains (loss)” of these securities (i.e., fair value versus amortized book value) as a separate component of “other comprehensive loss” on the accompanying Consolidated Statements of Comprehensive Loss for the year ended December 31, 2019.

Schedule of Property and Equipment Net of Accumulated Depreciation

“Property and equipment, net of accumulated depreciation” consists of the following:

	December 31,
	2019			2018
Manufacturing equipment*	$	10,355		$	—
Computers hardware and software	3,606			3,079
Laboratory equipment	36			635
Office furniture	248			212
Leasehold improvements	3,374			2,957
Property and equipment, at cost	17,619			6,883
(Less): Accumulated depreciation	(6,012		)	(6,498		)
Property and equipment, net of accumulated depreciation	$	11,607		$	385

* This account is comprised of our owned ROLONTIS production equipment on location at our contract manufacturer. This equipment has alternative future use for the general production of various biologic agents. Accordingly, we have capitalized these purchases, rather than recording it as “research and development” expense, despite its current designation for the manufacture of pre-FDA approved product. The majority of this manufacturing equipment was not in use and therefore not being depreciated as of December 31, 2019.

Schedules of Concentration of Risk, by Risk Factor

A summary of our customers that represent 10% or more of our accounts receivables as of December 31, 2019 and 2018, are as follows:

	December 31,
	2019				2018
McKesson Corporation and its affiliates	$	9	2.0	%	$	7,615	25.5	%
AmerisourceBergen Corporation, and its affiliates	—		—	%	10,448		35.0	%
Cardinal Health, Inc. and its affiliates	—		—	%	8,228		27.5	%
All other customers	432		98.0	%	3,582		12.0	%
Accounts receivable, net	$	441	100.0	%	$	29,873	100.0	%

Schedule of Prepaid Expenses and Other Assets

“Prepaid expenses and other assets” consists of the following:

	December 31,
	2019		2018
Vendor deposits	$	8,740	$	6,792
Prepaid insurance	1,408		782
Prepaid expenses and other assets	$	10,148	$	7,574

Schedule of Other Receivables

“Other receivables” consists of the following:

	December 31,
	2019		2018
CASI other receivables	$	2,393	$	—
Other miscellaneous receivables (including Medicaid rebate credits and royalty receivables from licensees)	1,490		1,189
Insurance receivable*	4,015		206
Income tax receivable - current portion	973		643
Interest receivable from marketable securities (see Note 3(a))	561		—
Reimbursements due from development partners for incurred research and development expenses	126		135
Secured promissory note (see Note 8)	—		1,525
Other receivables	$	9,558	$	3,698

* This insurance receivable balance represents our incurred legal fees and pending and completed settlements that are expected to be

reimbursed by our insurance carriers.

Summary of Other Assets

“Other assets” consists of the following:

	December 31,
	2019		2018
Key employee life insurance – cash surrender value (associated with our deferred compensation plan - see Note 7	$	3,547	$	6,274
Research & development supplies and other	119		246
Income tax receivable - non-current portion*	334		668
Other assets	$	4,000	$	7,188

* This value represents the non-current portion of refundable alternative minimum tax payments that are expected to be received over the next few years (see Note 11).

Assets And Liabilities, Leases

“Facility and equipment under lease” consists of the following:

	December 31, 2019		December 31, 2018
Office and research facilities	$	3,391	$	—
Office equipment	415		—
Facility and equipment under lease	$	3,806	$	—

The below table summarizes these lease asset and liability accounts presented on our accompanying Consolidated Balance Sheets:

Operating Leases*	Consolidated Balance Sheet Caption	December 31, 2019
Operating lease right-of-use assets - non-current	Facility and equipment under lease	$	3,806
Operating lease liabilities - current	Accounts payable and other accrued liabilities	$	1,683
Operating lease liabilities - non-current	Other long-term liabilities	2,372
Total lease liabilities		$	4,055

* As of December 31, 2019, we have no “finance leases” as defined in Topic 842.

Schedule of Accounts Payable and Other Accrued Obligations

“Accounts payable and other accrued liabilities” consists of the following:

	December 31,
	2019		2018
Trade accounts payable and other	$	32,012	$	44,919
Lease liability - current portion	1,683		—
Accrued commercial/Medicaid rebates*	2,925		8,580
Accrued product royalty due to licensors	66		4,337
Allowance for product returns	4,714		5,171
Accrued data and distribution fees	768		3,248
Accrued GPO administrative fees	6		296
Accrued inventory management fees	364		388
Allowance for government chargebacks*	11,746		14,373
Accounts payable and other accrued liabilities	$	54,284	$	81,312

* The values in 2018 have been restated for certain immaterial corrections related to “Accrued commercial/Medicaid rebates” and “Allowance for government chargebacks.” (see Note 15).

Schedule of Amounts Presented in Accounts Payable and Other Accrued Obligations

Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Consolidated Balance Sheets for GTN estimates (see Note 2(i)) were as follows:

Description	Commercial/Medicaid Rebates and Government Chargebacks*			Distribution, Data, Inventory, and GPO Administrative Fees			Product Return Allowances
Balance as of December 31, 2017	$	21,480		$	5,727		$	4,045
Add: GTN accruals recorded for product sales	69,704			13,962			1,700
(Less): Payments made and credits against GTN accruals	(68,232		)	(15,757		)	(574		)
Balance as of December 31, 2018	22,952			3,932			5,171
Add: GTN accruals recorded for product sales	7,702			1,209			167
(Less): Payments made and credits against GTN accruals	(15,983		)	(4,003		)	(624		)
Balance as of December 31, 2019	$	14,671		$	1,138		$	4,714

* The values in 2018 and 2017 have been restated for certain immaterial corrections related to “Commercial/Medicaid Rebates and Government Chargebacks.” (see Note 15).

Deferred Revenue

“Contract liabilities” consists of the following:

	December 31,
	2019		2018
Customer deposit for EVOMELA supply in China territory (see Note 8)	$	—	$	4,850
Contract liabilities	$	—	$	4,850

Summary of Other Long-Term Liabilities

“Other long-term liabilities” consists of the following:

	December 31,
	2019		2018
Deferred compensation liability (Note 10(f))	$	8,597	$	5,474
Lease liability - non-current portion (Note 10(a))	2,372		—
Other tax liabilities	101		176
Other long-term liabilities	$	11,070	$	5,650